Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
TIlray Brands, Inc. (TLRY) generates frequent news as a global lifestyle and consumer packaged goods company active across cannabis, beverage, wellness, and entertainment categories. Company updates often highlight developments in its cannabis brands, medical cannabis operations, beverage portfolio, and strategic corporate actions, giving investors and followers insight into how Tilray is executing its multi-category strategy.
News coverage commonly includes financial results and segment performance across cannabis, beverage, wellness, and distribution, as reflected in Tilray’s quarterly earnings releases. These updates may discuss trends in international medical cannabis revenue, Canadian adult-use cannabis sales, and distribution activity through Tilray Pharma. Corporate announcements, such as the implementation of a one-for-ten reverse stock split and related shareholder decisions, are also reported through press releases and SEC filings.
Tilray’s brand and product news provides detail on new launches and category expansion. Recent communications feature Dry January and holiday guides showcasing hemp-derived THC beverages, zero-proof spirits, non-alcoholic beers, and craft beers, as well as cannabis-infused beverages under brands like Mollo and XMG. Other releases focus on innovations in cannabis vapes and concentrates under brands such as Good Supply and Redecan, and curated cannabis gift guides that reflect consumer trends in Canada.
Regulatory and medical developments are another important theme. Tilray Medical has issued statements on U.S. federal cannabis rescheduling and the creation of Tilray Medical USA, outlining a framework for U.S. medical cannabis expansion based on experience in regulated international markets. For readers tracking TLRY, this news stream offers context on how the company responds to policy changes, evolves its brand portfolio, and communicates with shareholders. Bookmark this page to access an organized feed of Tilray’s earnings releases, product announcements, regulatory updates, and other material company news.
Tilray Brands (NASDAQ: TLRY) says federal rescheduling of cannabis to Schedule III creates an inflection point for U.S. medical cannabis access, clinical research, and industry standardization. The company highlights 7 million square feet of cultivation capacity and experience serving hundreds of thousands of patients in 20+ countries.
Tilray says it is prepared to scale pharmaceutical-quality cultivation, manufacturing, and distribution in the U.S., and is evaluating participation in a CMMI pilot to supply hemp-derived medical cannabis to accountable care organizations and oncology practices.
BrewDog USA (NASDAQ: TLRY) unveiled its spring/summer lineup on April 23, 2026, emphasizing innovation across core beers and emerging beverage categories. Key highlights include Elvis Juice (6.5% ABV), new nonalcoholic Juice Club in four expressions, Hazy Jane (7.2% ABV) and lower‑alcohol Baby Hazy (3.2% ABV). The company cites accelerated product development from its Columbus pilot brewery and a summer marketing push tied to on‑trade and community initiatives.
Tilray Brands (Nasdaq: TLRY) marked 4/20 on April 20, 2026, reaffirming its leadership in medical cannabis and commitment to patient care.
The company highlights a science-driven global platform, 150+ medical products, support for 400,000 patients, and integrated pharmaceutical-grade cultivation, clinical research, and distribution.
Tilray (Nasdaq: TLRY) launched PORTAL on April 8, 2026, a high‑intensity cannabis brand targeting experienced, high‑tolerance consumers across Canada.
PORTAL debuts infused pre‑rolls and liquid‑diamond vapes with THCA diamond coatings and products ranging from >40% THC pre‑rolls to 95–99% THC cartridges, available at select provincial retailers.
Breckenridge Distillery (NASDAQ: TLRY) relaunched Breckenridge Honey Whiskey on April 7, 2026, an expression infused with rare Goldswarm Raw Honey from Nigeria.
It is bottled at 36% ABV (72 proof), available in 750ml, 1L, 1.75L and 50ml formats, with Colorado retailers now and national retail availability planned for mid‑April.
Tilray Brands (Nasdaq: TLRY) reported record Q3 fiscal 2026 results for quarter ended Feb 28, 2026: net revenue $206.7M (+11% YoY) and gross profit $55.0M (+6% YoY). Cannabis net revenue rose to $64.8M (+19%), led by international cannabis +73%. Distribution net revenue reached a record $83.0M. Adjusted EBITDA was $10.7M (+19%). Cash, restricted cash and marketable securities totaled $264.8M and net cash improved to $3.5M versus prior-year net debt. BrewDog acquisition (~£40M) closed after quarter end and is not reflected in results. Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $62M–$72M while noting geopolitical risks could affect outlook.
Tilray Beverages (TLRY) brand Shock Top launched High Voltage, its first high-ABV double wheat beer, at 9.6% ABV in 19.2 oz cans priced from $2.99. The beer features orange peel and orange puree, bright citrus notes, and a smooth wheat finish. A Southern California debut precedes nationwide expansion to large-format and convenience stores beginning in May.
According to the company, High-ABV singles led craft spending in 2025, and High Voltage is positioned to capture that trend with a bold citrus-forward profile and on-premise/off-premise rollout.
Tilray Brands (Nasdaq: TLRY) announced a licensing partnership with The Magnum Ice Cream Company to launch Popsicle Hard ready-to-drink malt beverages in the U.S. The line features 5% ABV Hard Cherry, Hard Orange and Hard Grape in a variety pack rolling out March 2026 at major retailers.
The red-white-and-blue Popsicle Hard Firecracker flavor will follow in May 2026 in 12-packs of 12-ounce slim cans. Products will be sold at Walmart, Kroger, Albertson's, Safeway, Food Lion, Ingles and Buc-ees. More info at www.popsiclehard.com.
Tilray Brands (Nasdaq: TLRY) will release third fiscal quarter results for the period ended February 28, 2026 before markets open on Wednesday, April 1, 2026. The company will host a live conference call and audio webcast at 8:30 AM ET the same day.
Investors can access the webcast via the Events & Presentations section of Tilray's Investor Relations website for results discussion and Q&A.
Tilray Medical (NASDAQ: TLRY) announced its largest medical cannabis portfolio expansion in Australia on March 19, 2026, adding new products across multiple formats to increase patient access within Australia’s regulated medical system.
The expansion will introduce Redecan extracts, flower, vapes and pastilles, and Good Supply flower offerings over the coming months.